M&A Deal Summary

Cempra Pharmaceuticals Acquires Melinta Therapeutics

On August 9, 2017, Cempra Pharmaceuticals acquired life science company Melinta Therapeutics from Warburg Pincus and Malin

Acquisition Highlights
  • This is Cempra Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Cempra Pharmaceuticals’ 1st transaction in the United States.
  • This is Cempra Pharmaceuticals’ 1st transaction in Connecticut.

M&A Deal Summary
Date 2017-08-09
Target Melinta Therapeutics
Sector Life Science
Buyer(s) Cempra Pharmaceuticals
Sellers(s) Warburg Pincus
Malin
Deal Type Merger
Advisor(s) J.P. Morgan Securities (Financial)
Willkie Farr & Gallagher (Legal)

Target

Melinta Therapeutics

New Haven, Connecticut, United States
Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cempra Pharmaceuticals

Chapel Hill, North Carolina, United States
Category Company
Sector Life Science
DESCRIPTION

Development stage biotechnology company focused on infectious disease. It was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1

Seller(S) 2

SELLER

Warburg Pincus

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1966
PE ASSETS 83.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Warburg Pincus is a mega-sized, global private equity firm focused on investment opportunities across North America, Asia, and Europe. Warburg will consider investing at various company stages, from early-stage opportunities to distressed situations. Warburg Pincus is organized by industry groups. Verticals include financial services, healthcare, technology, media & telecommunications, energy, consumer & industrial, and real estate. Within financial services, Warburg will consider asset/wealth managers, banks, exchanges, financial technology, insurance, transaction processing, private banking, and specialty/consumer finance. Within healthcare, specific areas of interest include medical devices, healthcare services, and biotech/pharmaceuticals. Within technology/media/communications, Warburg targets software, media/internet/information, financial technology, telecom, business services, and systems/semiconductors. Within energy, specific areas of interest include oil/gas exploration, power generation/transmission, and alternative energy. Warburg Pincus raised its first fund in 1966 and is based in New York City.

DEAL STATS #
Overall 150 of 251
Sector (Life Science) 17 of 20
Type (Merger) 5 of 12
State (Connecticut) 2 of 2
Country (United States) 91 of 137
Year (2017) 12 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-01 Evidon

New York, New York, United States

Evidon, Inc. is a technology company focused on simplifying the complex world of Digital Governance. Fulfilling this promise requires organisations to have a comprehensive approach to govern data collection across their websites, applications and ads while complying with global regulations. Evidon, Inc. was established in 2009 and is based in New York, New York.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-21 Kontron

Augsburg, Germany

Kontron is a manufacturer of embedded computer technology (ECT) and supplier of OEMs, system integrators and application providers in a broad range of market segments, including data and telecommunications, automation, mobile computing, medical technology, military technology, aerospace, and measuring and control engineering. Kontron is based in Augsburg, Germany.

Sell -
SELLER

Malin

Dublin, Ireland
Category Company
Founded 2014
Sector Life Science
Employees255
Revenue 41M EUR (2020)
DESCRIPTION

Malin is a globally operating life sciences company. Malin was founded in 2014 and is based in Dublin, Ireland.

DEAL STATS #
Overall 1 of 6
Sector (Life Science) 1 of 4
Type (Merger) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 2
Year (2017) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-06 Artizan Biosciences

Durham, North Carolina, United States

Artizan Biosciences, Inc. is a biotechnology companyfocused on drug discovery and development for diseases involving the human intestinal microbiota. Artizan has developed a proprietary platform for distinguishing pathogenic bacteria from the remainder of the intestinal microbiota and has a therapeutic strategy to target these bacteria as treatment for inflammatory bowel diseases (IBD).

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-27 3D4Medical

Dublin, Ireland

3D4Medical Ltd. specializes in the development of medical, educational and health and fitness apps for healthcare professionals as well as student and patient education.

Sell -
Mergr

Product

Company

Legal